SCHEMBL18038976

SCHEMBL18038976

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1cccc(-c2ccc(-c3ccc4ccccc4c3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ MCOLN3 Q8TDD5 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ MAPT P10636 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ AKR1C3 P42330 1/20 0.40
▸ AKR1C1 Q04828 1/20 0.40
▸ PKM P14618 3/20 0.40
▸ IL1RN P18510 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038987 0.93 MCOLN3 (0.49) L3MBTL1MCOLN3TSHRALDH1A1GAA
SCHEMBL18039003 0.93 MCOLN3 (0.49) L3MBTL1MCOLN3TSHRALDH1A1GAA
SCHEMBL18038951 0.93 L3MBTL1 (0.52) L3MBTL1TSHRALDH1A1GAAMKNK1
SCHEMBL18038979 0.93 L3MBTL1 (0.52) L3MBTL1TSHRALDH1A1GAAMKNK1
SCHEMBL18038943 0.92 L3MBTL1 (0.53) L3MBTL1TSHRALDH1A1GAAMAPT
SCHEMBL18038990 0.91 L3MBTL1 (0.52) L3MBTL1TSHRALDH1A1GAAMAPT
SCHEMBL18039014 0.90 L3MBTL1 (0.52) L3MBTL1TSHRALDH1A1GAAMAPT
SCHEMBL18038946 0.89 L3MBTL1 (0.46) L3MBTL1TSHRALDH1A1GAAMEN1
SCHEMBL18038974 0.88 L3MBTL1 (0.48) L3MBTL1ALDH1A1GAAMEN1KMT2A
SCHEMBL18038965 0.87 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885MCOLN3 3546/4885TSHR 4787/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885MCOLN3 3621/4885TSHR 4793/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885MCOLN3 3546/4885TSHR 4787/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885MCOLN3 3621/4885TSHR 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback